In particular, the cytostatic effect of Etomoxir agrees with data showing a cell cycle arrest in Caki-1 and 786-O ccRCC cell lines treated with Peroxisome proliferator-activated receptor a (PPARa) antagonists [26] that, downregulating the PPARa target CPT1 [27], might in part reproduce the metabolic and functional effects of Etomoxir. This evidence concerns the gene PPARA and nonpapillary renal cell carcinoma.